Atherosclerotic cardiovascular disease: a review of initiators and protective factors

Inflammopharmacology

Volumn 24, Issue 1, 2016, Pages 1-10

  Ellulu, Mohammed S ^a   Patimah, Ismail ^a   Khaza’ai, Huzwah ^a   Rahmat, Asmah ^a   Abed, Yehia ^b   Ali, Faisal ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b AL QUDS UNIVERSITY   (Palestine)

Author keywords

Endothelial dysfunction; Hepatic apoE; Inflammation; Lipoprotein oxidation; Matrix metalloproteinases; NAD(P)H oxidase; Reactive oxygen species, ROS; SERCA2a; Thrombosis

Indexed keywords

APOLIPOPROTEIN E; CALCIUM; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; CYTOPLASM; ENDOTHELIAL DYSFUNCTION; FOAM CELL; GENE EXPRESSION; HEART MUSCLE CONTRACTILITY; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOSIS; ANIMAL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTECTION;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LIPID PEROXIDATION; NITRIC OXIDE; OXIDATIVE STRESS; PROTECTIVE FACTORS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84957553576     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-015-0255-y     Document Type: Review

References (60)

1. Agha A, Schlüter H, König S, Biel K, Tepel M, Zidek W (1992) A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives. J Vasc Res 29(3):281–289
2. Arai M, Matsui H, Periasamy M (1994) Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 74(4):555–564
3. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115(Pt 19):3719–3727
4. Borén J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL (1998) Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 101(12):2658–2664
5. Bourassa MG, Tardif JC (eds) (2006) Antioxidants and cardiovascular disease, 2nd edn. Springer Science & Business Media. ISBN: 978-0387-29552-7
6. Camejo G, Fager G, Rosengren B, Hurt-Camejo E, Bondjers G (1993) Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 268(19):14131–14137
7. Collins T, Cybulsky MI (2001) NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107(3):255–264
8. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M et al (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107(10):1255–1262
9. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE (1995) Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 92(9):2540–2549
10. Ferrari P, Micheletti R, Valentini G, Bianchi G (2007) Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure. Med Hypotheses 68(5):1120–1125
11. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408(6809):239–247
12. Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP, Borén J (2002) Identification of the proteoglycan binding site in apolipoprotein B48. J Biol Chem 277(35):32228–32233
13. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94(6):2493–2503
14. Gotto AM Jr, Farmer JA (1988) Risk factors for coronary artery disease. In: Braunwald E (ed) Heart disease: a textbook of cardiovascular medicine. Saunders, Philadelphia, pp 1153–1190
15. Gotto AM Jr, Grundy SM (1999) Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation 99:E1–E7
16. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H et al (2003) Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD (P) H oxidase–derived reactive oxygen species. Circ Res 92(11):e80–e86
17. Hakim J (1993) Reactive oxygen species and inflammation. C R Seances Soc Biol Fil 187(3):286–295
18. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 75(3):434–442
19. Higashi Y, Noma K, Yoshizumi M, Kihara Y (2009) Endothelial function and oxidative stress in cardiovascular diseases. Circ J 73(3):411–418
20. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M et al (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88(2):e14–e22
21. Krötz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM et al (2002) NAD(P)H-oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100:917–924
22. Krötz F, Sohn HY, Pohl U (2004) Reactive oxygen species players in the platelet game. Arterioscler Thromb Vasc Biol 24(11):1988–1996
23. Kuipers F, Jong MC, Lin Y, Eck MV, Havinga R, Bloks V et al (1997) Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest 100(11):2915–2922
24. Lakshmi SV, Padmaja G, Kuppusamy P, Kutala VK (2009) Oxidative stress in cardiovascular disease. Indian J Biochem Biophys 46:421–440
25. Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32(9):2045–2051. doi:10.1161/ATVBAHA.108.179705
26. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135–1143
27. Loscalzo J (2003) Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans 31(Pt 5):1059–1061
28. Lüscher TF (1990) Imbalance of endothelium-derived relaxing and contracting factors a new concept in hypertension? Am J Hypertens 3(4):317–330
29. Mahley RW, Huang Y (1999) Apolipoprotein E: from atherosclerosis to Alzheimer’s disease and beyond. Curr Opin Lipidol 10(3):207–217
30. Mahley RW, Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1(1):507–537
31. Mahley RW, Weisgraber KH, Huang Y (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res 50(Suppl):S183–S188. doi:10.1194/jlr.R800069-JLR200
32. Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12(12):1075–1095
33. Maugeais C, Tietge UJ, Tsukamoto K, Glick JM, Rader DJ (2000) Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J Lipid Res 41(10):1673–1679
34. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y et al (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers—smoking as a cause of oxidative damage. N Engl J Med 332(18):1198–1203
35. 2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 17(1):61–63
36. Nievelstein PF, Fogelman AM, Mottino G, Frank JS (1991) Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscler Thromb 11(6):1795–1805
37. Patruno A, Pesce M, Marrone A, Speranza L, Grilli A, De Lutiis MA et al (2012) Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells. J Cell Physiol 227(6):2767–2774. doi:10.1002/jcp.23024
38. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635–1701. doi:10.1093/eurheartj/ehs092
39. Pratico D, Pasin M, Barry OP, Ghiselli A, Sabatino G, Iuliano L et al (1999) Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation 99:3118–3124
40. Proctor SD, Vine DF, Mamo JC (2002) Arterial retention of apolipoprotein B48-and B100-containing lipoproteins in atherogenesis. Curr Opin Lipidol 13(5):461–470
41. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE (1999) Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 99(23):2979–2982
42. Radomski MW, Palmer RM, Moncada S (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2:1057–1105
43. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS (1996) Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98(11):2572–2579
44. Rao GN, Berk BC (1992) Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70(3):593–599
45. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brümmer J et al (2004) Urinary 8-iso-prostaglandin F2α as a risk marker in patients with coronary heart disease a matched case-control study. Circulation 109(7):843–848
46. Simionescu M, Simionescu N (1993) Proatherosclerotic events: pathobiochemical changes occurring in the arterial wall before monocyte migration. FASEB J 7(14):1359–1366
47. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP et al (2002) Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105(12):1429–1435
48. Sottero B, Gargiulo S, Russo I, Barale C, Poli G, Cavalot F (2015) Postprandial dysmetabolism and oxidative stress in type 2 diabetes: pathogenetic mechanisms and therapeutic strategies. Med Res Rev 35(5):968–1031. doi:10.1002/med.21349
49. Steinberg D (2002) Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 8(11):1211–1217
50. Steinbrecher U, Parthasarathy S, Leake DS, Witztum JL, Steinberg D (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci 81(12):3883–3887
51. Stocker R, Keaney JF (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84(4):1381–1478
52. Sugamura K, Keaney JF (2011) Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 51(5):978–992. doi:10.1016/j.freeradbiomed.2011.05.004
53. Taleb A, Witztum JL, Tsimikas S (2011) Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 5(5):673–694. doi:10.2217/bmm.11.60
54. Tong X, Evangelista A, Cohen RA (2010) Targeting the redox regulation of SERCA in vascular physiology and disease. Curr Opin Pharmacol 10(2):133–138. doi:10.1016/j.coph.2009.11.008
55. Trogdon JG, Finkelstein EA, Nwaise IA, Tangka FK, Orenstein D (2007) The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract 8(3):234–242
56. Turpaev KT (2002) Reactive oxygen species and regulation of gene expression. Biochemistry (Mosc) 67(3):281–292
57. Véniant MM, Pierotti V, Newland D, Cham CM, Sanan DA, Walzem RL et al (1997) Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 100(1):180–188
58. Watanabe N, Ikeda U (2004) Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 6(2):112–120
59. Zalba G, San José G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ et al (2001) Oxidative stress in arterial hypertension role of NAD(P)H oxidase. Hypertension 38(6):1395–1399
60. Zheng JS, Yang XQ, Lookingland KJ, Fink GD, Hesslinger C, Kapatos G et al (2003) Gene transfer of human guanosine 5′-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation 108(10):1238–1245